Comparative Pharmacology
Head-to-head clinical analysis: MELFIAT 105 versus SANOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELFIAT 105 versus SANOREX.
MELFIAT-105 vs SANOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting reuptake of serotonin at the presynaptic neuronal membrane.
Serotonin 5-HT2C receptor agonist; stimulates pro-opiomelanocortin (POMC) neurons, leading to release of α-melanocyte-stimulating hormone (α-MSH) and activation of melanocortin-4 receptors in the hypothalamus, reducing appetite.
105 mg orally once daily in the morning.
Oral: 1 mg twice daily for 12 weeks; maximum dose: 2 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 4-6 hours, supporting twice-daily dosing in clinical practice.
Terminal elimination half-life: 2-4 hours; context: requires multiple daily dosing to maintain therapeutic effect.
Approximately 90% of an administered dose is excreted renally as unchanged drug and metabolites, with the remainder eliminated via biliary/fecal routes.
Renal: 90% unchanged; biliary/fecal: 10%
Category C
Category C
Anorexiant
Anorexiant